Solutions Through Advanced Research, Inc | Jacksonville, FL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.
Must self-identify as either Black or African American in race in the open label addenda.
Have severe or very severe AA, as determined by all of the following:
Male or nonpregnant, nonbreastfeeding female participants.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
824 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal